Anaplastic Thyroid Cancer: An Aggressive Type of Cancer
Written by John P. Sabra, MD FACS
Updated September 2026
Educational only. This article is not medical advice. Always consult your physician about your individual situation.
Anaplastic thyroid cancer is the rarest and most aggressive form of thyroid cancer. It accounts for fewer than 2% of thyroid cancer diagnoses, but it is responsible for a disproportionate share of thyroid cancer deaths. This disease is serious, and treatment must begin quickly. New targeted therapies have meaningfully changed what outcomes are possible for the right select patients.
The first thing to know about anaplastic thyroid cancer is that it is not on the same spectrum as papillary or follicular thyroid cancer. The cells have undergone a process called dedifferentiation, meaning they have lost the features that make thyroid cells recognizable as thyroid cells. They no longer take up iodine. They no longer produce thyroglobulin. They no longer respond to thyroid-stimulating hormone (TSH). They grow rapidly, invade nearby structures, and frequently spread to distant sites within weeks or months.
The second thing to know is that the overall prognosis has changed for the better over the past five years. The discovery that approximately 25 to 40% of anaplastic thyroid cancers carry a specific genetic mutation called BRAF V600E, along with the availability of drugs that target this mutation, has produced responses in some patients that would have been unthinkable a decade ago. This is not yet a routinely curable disease. But for the right patient, with the right molecular profile, treated at a center experienced with this diagnosis, real responses are now possible.
How Anaplastic Thyroid Cancer Presents
Anaplastic thyroid cancer most commonly affects patients in their 60s and 70s. The classic presentation is a rapidly growing neck mass over weeks to months, often with hoarseness, difficulty swallowing, or pressure on the airway. Many patients have a prior history of a thyroid nodule that was slow-growing for years and then suddenly accelerated, which represents transformation of an existing differentiated thyroid cancer into an anaplastic form. This is one of the reasons long-standing benign-appearing thyroid masses still warrant periodic surveillance.
The diagnosis is confirmed by a needle biopsy. Because this cancer grows quickly, the workup must also move quickly: imaging of the neck, chest, and brain, BRAF mutation testing, and assessment of the airway should all happen within days, not weeks. Approximately 40 to 50% of patients have distant metastases at the time of diagnosis, most commonly to the lungs.
Anaplastic thyroid cancer is one of the few thyroid cancer diagnoses that is a true medical urgency. The American Thyroid Association recommends that BRAF mutation testing be performed within 72 hours of diagnosis, and that a comprehensive treatment plan be in place within one week. The treatment center should have an experienced multidisciplinary team including endocrine surgery, medical oncology, radiation oncology, and endocrinology. This is not a diagnosis to manage at a community hospital.
Why BRAF Testing is Important
The BRAF V600E mutation is a specific genetic change found in approximately 25 to 40% of anaplastic thyroid cancers. When this mutation is present, the cancer can be treated with a combination of two targeted drugs (dabrafenib and trametinib), which block the abnormal signaling pathway driven by the mutation.
The combination has produced response rates of approximately 60% in BRAF-mutated anaplastic thyroid cancer, with some patients achieving disease control measured in months to years rather than weeks. In selected cases, the response to targeted therapy has been substantial enough to convert previously unresectable disease into operable disease, an approach called neoadjuvant targeted therapy followed by surgery. This represents a fundamental change from the older approach of palliative treatment alone.
Treatment Options
Treatment of anaplastic thyroid cancer is highly individualized and depends on whether the disease is resectable, what the molecular profile shows, and the overall health of the patient.
| Disease Stage | Standard Approach |
|---|---|
| Resectable, confined to neck | Surgical resection if a complete removal is feasible, followed by external beam radiation and systemic therapy. |
| Unresectable, BRAF-mutated | Dabrafenib plus trametinib targeted therapy. Surgery may be reconsidered if the tumor shrinks substantially. |
| Unresectable, BRAF wild-type | Chemotherapy plus radiation, immunotherapy in selected patients, and clinical trial enrollment when available. |
| Airway compromise | Urgent evaluation for tracheostomy or stent placement to secure the airway before other treatment proceeds. |
Surgery alone is rarely curative for anaplastic thyroid cancer. Even when the tumor appears localized, microscopic disease almost always extends beyond what can be removed. Surgery is most useful when combined with systemic therapy and radiation in a planned multimodality approach.
Prognosis
Overall survival in anaplastic thyroid cancer remains poor, with median survival measured in just months in historical series. Survival statistics from before the era of BRAF-targeted therapy are no longer fully representative for the subset of patients with targetable mutations. Patients with localized BRAF-mutated disease treated with modern multimodality therapy have meaningfully longer survival than the historical numbers suggest. Anaplastic thyroid cancer is serious, complete cure remains uncommon, but meaningful prolonged disease control is achievable for some patients with the right treatment.
Goals of care conversations are an important part of managing anaplastic thyroid cancer from the beginning. A patient with this diagnosis should be making decisions in partnership with a team that can offer aggressive treatment when appropriate and palliative-focused care when that aligns better with what matters most. The right path depends on the molecular profile, the extent of disease, the patient’s overall health, and the patient’s own values.
What to Ask Your Team
-
BRAF mutation status: Has BRAF V600E testing been performed, and what is the result? This is the single most important molecular question.
-
Multidisciplinary review: Has the case been presented at a tumor board including endocrine surgery, medical oncology, radiation oncology, and endocrinology?
-
Airway plan: What is the plan if breathing becomes compromised?
-
Clinical trial eligibility: Are there active clinical trials for which you may qualify? Anaplastic thyroid cancer trials often have rolling enrollment.
-
Center experience: How many cases of anaplastic thyroid cancer has this team managed?
The Bottom Line
Anaplastic thyroid cancer is a serious diagnosis that requires immediate, coordinated, expert care. It is not the same disease as papillary or follicular thyroid cancer and cannot be approached with the same framework. The most important early decisions are getting to a high-volume center with experience in anaplastic thyroid cancer, completing BRAF mutation testing promptly, and ensuring that the airway is protected throughout the course of treatment.
This article is intended for patient education only. It does not constitute medical advice and does not replace a consultation with your physician. Individual patient circumstances and clinical judgment determine the appropriate evaluation and management for every patient.
More from the Thyroid Cancer series
Ready to Talk to a Specialist?
A thyroid specialist can review your specific results, answer your questions, and help you understand exactly what your next steps should be. The ATLAS network connects you with experienced thyroid and parathyroid expert physicians who focus on thyroid disease.
Find a Thyroid Specialist Near You →